Reply to: "Overlapping Ranges in Levels Indicate That Hexosylsphingosine Is Not a Clinically Relevant Biomarker for GBA1-Associated Parkinson's Disease"

Mov Disord. 2022 Aug;37(8):1781-1782. doi: 10.1002/mds.29131.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Intramural
  • Comment

MeSH terms

  • Biomarkers
  • Glucosylceramidase / genetics
  • Humans
  • Mutation
  • Parkinson Disease* / diagnosis
  • Parkinson Disease* / genetics
  • alpha-Synuclein

Substances

  • Biomarkers
  • alpha-Synuclein
  • Glucosylceramidase